Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
Stopped early · Phase 2/Phase 3
Conditions studied: Peripheral Vascular Disease
In brief
Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an out-patient basis. The study will be conducted at multiple centers.
Key facts
- Study ID
- NCT00067041
- Run by
- United Therapeutics
- People needed
- 30
- Starts
- 2003-03-01
- Expected to finish
- 2003-12-01
- Last updated by the study team
- 2013-03-07
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Southern Illinois University School of Medicine — Springfield, Illinois, United States
- University of Massachusetts Memorial Health Center — Worcester, Massachusetts, United States
- Vascular Institute Albany Medical College — Albany, New York, United States
- Oregon Health Sciences University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.